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To achieve complete polio eradication, the live oral poliovirus vaccine (OPV) currently used must be phased out
after the end of wild poliovirus transmission. However, poorly understood threats may arise when OPV use is
stopped. To counter these threats, better models than those currently available are needed. Two articles recently
published in BMC Medicine address these issues. Mercer et al. (BMC Med 15:180, 2017) developed a statistical model
analysis of polio case data and characteristics of cases occurring in several districts in Pakistan to inform resource
allocation decisions. Nevertheless, despite having the potential to accelerate the elimination of polio cases, their
analyses are unlikely to advance our understanding OPV cessation threats. McCarthy et al. (BMC Med 15:175, 2017)
explored one such threat, namely the emergence and transmission of serotype 2 circulating vaccine derived
poliovirus (cVDPV2) after OPV2 cessation, and found that the risk of persistent spread of cVDPV2 to new areas
increases rapidly 1–5 years after OPV2 cessation. Thus, recently developed models and analysis methods have the
potential to guide the required steps to surpass these threats. ‘Big data’ scientists could help with this; however,
datasets covering all eradication efforts should be made readily available.
Please see related articles: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0937-y and
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0941-2.
Keywords: Polio eradication, Polio transmission models, Dynamic system analysis, Complex system inference,
Inference robustness assessment, POMP
Background
Polio eradication is the greatest global communitarian
effort undertaken by humankind, thus failure to eradi-
cate polio would be a global catastrophe. Nevertheless,
eradication is complicated given the fact that success
must be followed by complete global elimination of the
oral poliovirus vaccine (OPV), without which, however,
global eradication of polio is not possible. Elimination of
the OPV is needed due to the threat of the poliovirus
reacquiring wild poliovirus (WPV) characteristics and
becoming circulating live vaccine-derived polioviruses
(cVDPV), hindering full eradication of all pathogenic
polioviruses. Thus, the Global Polio Eradication Initiative
(GPEI) has been tasked with ensuring that all remaining
OPV is destroyed after cessation of its use [1]. The three
serotypes of WPV1–3 have varying characteristics,
presenting different issues for polio eradication. WPV1 re-
mains active and causing polio, whereas WPV2 and WPV3
were last detected in 1999 and 2012, respectively [2]. The
elimination of WPV2 was relatively easy due to the high
transmissibility of the OPV; however, this also led to a high
rate of cVDPV2 emergence. WPV3 elimination has differ-
ent dynamics because OPV3 is the least transmissible OPV
and this could lead to prolonged silent circulation after the
last polio case [2]. Global cessation of OPV2 occurred in
April 2016. All trivalent OPV containing all three strains
was destroyed and the standard OPV became bivalent
OPV with only strains 1 and 3. Since then, cVDPV2 has
been found in Nigeria, Pakistan, Syria, and the Congo [3].
Modeling progress to achieve eradication
The combination of models and data can help eliminate
the incidence of WPV1-caused cases and increase our
understanding of how to reduce the likely threats arising
from all three WPV strains upon cessation of their
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corresponding OPV. An article by Mercer et al. [4] in
BMC Medicine addresses resource allocation to achieve
the most efficient elimination of WPV1 cases in
Pakistan. A further article by McCarthy et al. [5]
addresses threat onset upon OPV2 cessation. These two
papers advance methods within two different types of
model analyses that can assist polio eradication.
However, a third model analysis type (MAT) may be
needed to insure eradication.
The MAT discussed here simplify a complex diversity
of overlapping analytical methods into three categories.
MAT1 uses non-mechanistic statistical models to analyze
the associations between polio cases and predictor vari-
ables. This is the approach taken by Mercer et al. [4]
MAT2 uses mechanistic models of how polioviruses are
transmitted. These are constructed as mathematical
models or computer simulations on the basis of estab-
lished knowledge and/or assumptions. This is the
approach taken by McCarthy et al. [5] Often, MAT2
parameters are adjusted to fit past patterns of polio cases
without statistically estimating them. MAT3 fits mechan-
istic models to data in a more rigorous way, thus
providing estimates of parameters. MAT3 can uncover the
causal mechanisms generating observed patterns in data.
Insights into causal mechanisms are essential to predict
behavior in new situations that have never been experi-
enced before. That is the case for polio eradication where
we have never stopped OPV use before in situations
where vaccination has decreased transmission for long
periods without eliminating all cases. The technology used
for MAT3 is new and developing rapidly.
Progress in all three model types could help ensure
polio eradication. The first step toward eradication is
achieving zero polio cases. This has not been easy in
Pakistan. Mercer et al. [4] performed a MAT1 using data
from WPV1 polio cases, together with past history and
characteristics of local districts in Pakistan, to direct re-
sources towards districts wherein they will most benefit
eradication efforts. They made technical advances to
MAT1 that improve descriptions of how surveillance
variables track the risk of symptomatic infections. That,
in turn, strengthens the GPEI strategy of learning how
to refine eradication strategies by examining past experi-
ences. Nevertheless, the data and the theory used by
Mercer et al. cannot capture important issues that could
arise when OPV use is stopped.
One such issue was examined by McCarthy et al. [3],
who performed a MAT2 to model OPV2 cessation and
the subsequent discovery of a cVDPV2 in such a popula-
tion. The authors examined how local use of OPV2 to
control the detected cVDPV2 could lead to the emer-
gence of a new cVDPV2, which would subsequently
spread to a population where OPV2 cessation remains
in effect. Further, the authors showed that time since
OPV2 cessation increases the risk of this occurring and
examined how this risk is affected by migration rates,
basic reproduction numbers, the transmissibility of
OPV2 during its first stages of evolution into a cVDPV2,
levels of immunity at the time of OPV2 cessation, and
the use of inactivated polio vaccine. Additionally, the
risk of cVDPV2 survival that could cascade out of con-
trol was seen to rise quickly with increasing time since
OPV cessation, varying from 1 to 5 years as a function
of the different factors assessed. Their study offers a
useful advance in MAT2 methods by assessing the likeli-
hood of an unfavorable outcome with built-in methods
that simultaneously capture the effects of chance
processes and the uncertainty of parameters. Their
‘separatrix’ graphs provide a comprehensible view of
complex risk relationships. Given the ongoing cVDPV2
transmission in four locations now more than a year and
half since OPV2 cessation, their result bring urgency to
getting cVDPV2 under control.
The McCarthy et al. [3] model assumes there is no
waning of immunity and that all transmission occurs in
children under the age of 5 years with no immunity.
These simplifying assumptions helped delineate mecha-
nisms of cVDPV emergence and spread after OPV cessa-
tion. A next step to better understand such emergence
and spread should realistically relax those simplifying as-
sumptions. Doing so seems likely to further accelerate
the spread of cVDPV2 after OPV2 cessation. Their
assumptions of no waning and no transmission over age
five are countered by adult cases in Tajikistan [6] and
Xinjiang [7, 8]. These WPV1 outbreaks were caused by
viruses geographically and genetically related to those in
Pakistan. Additionally, confirmation of adequate prior
OPV vaccination of adults in the 1988 Israeli WPV1
polio epidemic [9] specifically supports waning as a
cause of those cases, as does the age pattern of dropping
neutralizing antibodies in a population with high OPV
coverage that eliminated WPV cases [10].
When these two assumptions are realistically relaxed, an
important issue arises related to the generalizability of the
inferences about high risk areas made by Mercer et al. [4].
The authors’ make no claims that their inferences about
where efforts to prevent future cases will be most pro-
ductive generalize to infections after the last case. Never-
theless, decision-makers might make such generalizations.
This would be inappropriate because transmission can
vary dramatically after detection of the last case depending
upon how many transmissions arise from adults with
waned immunity [11]. If waned immunity is sustaining si-
lent circulation, areas with low rates of WPV or OPV
transmission might have a higher chance of sustaining
transmission than those identified by the type of analysis
performed by Mercer et al. [4] since there would have
been less frequent boosting of immunity in those areas.
Koopman BMC Medicine  (2017) 15:221 Page 2 of 4
Polio eradication is now too close to elimination of all
paralytic cases for new fundamental science to elucidate
how polio immunity wanes and how that affects WPV or
OPV circulation. Therefore, MAT2 analytic approaches
cannot resolve how waning will affect either the
phenomenon of cVDPV persistence studied by McCarthy
et al. [3] or WPV persistence in the absence of detected
polio cases [11]. Instead, new approaches to linking
models and data using MAT3 model analyses are needed.
Using models to infer waning immunity effects on
threats to polio eradication
Since the beginning of eradication efforts, the GPEI has
gathered data obtained from acute flaccid paralysis sur-
veillance, special immunization activities, sequencing of
polio isolates, environmental surveillance, and various
special surveys. New MAT3 methods are able to employ
all such data in a single analysis to fit the parameters of
transmission system models and thus generate the
knowledge required to ensure an effective course to
polio eradication. An early development in these models
involves approximate Bayesian computation using se-
quential Monte Carlo fitting [12, 13]. More recent and
more powerful methods use a sequential Monte Carlo
approach, termed iterated particle filtering [14]. These
and other approaches are all included in the POMP
package for R [15], which this year saw a notable ad-
vance enabling the direct fitting of genetic sequence data
to models [16]. Other advances include new approaches
to inference robustness assessment and identifiability
analyses [17]. New models of immune response to infec-
tion and waning of immunity published in the past year
also make the use of these MAT3 methods more inform-
ative [18].
The task of informing eradication endgame decisions
must be completed by research from various groups and
a combination of unique approaches to modifying previ-
ously developed models, fitting those models to available
data in ways that generate new knowledge, and perform-
ing identifiability analyses that indicate what new data
will be most informative for good decision-making.
Openness will be a key to applying MAT3 analyses to
polio eradication. The particular history of GPEI en-
deavors in the context of WHO bureaucracy has under-
standably not promoted openness. However, this critical
juncture calls for change. We need to understand what
is impeding access to polio eradication program data
and take action to improve data availability. Bold leader-
ship, like that which launched the GPEI and continues
to guide it, cannot be paralyzed by uncertainty. The
hope is that the threats examined by McCarthy et al. [3],
as well as those related to silent circulation at the time
that OPV is stopped, never materialize. Nevertheless, the
huge costs of failure justify greater efforts to make GPEI
data available to the emerging cadre of scientists who
can determine how to minimize risks.
Conclusions
Modeling can uncover threats to polio eradication and
present the most cost-effective paths to overcoming
these threats. The two papers in BMC Medicine dis-
cussed herein make significant advances in this regard.
However, their methods cannot fully eliminate the key
uncertainties that could threaten eradication when OPV
use is stopped. Newly developed methods are therefore
needed. The complex nature of inference using these
methods requires analyses by multiple groups with
diverse perspectives and methodological skills. However,
the needed analyses will not happen without direct ac-
cessibility to GPEI data.
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